News >

Amid PARP Advances, Chemo Remains Critical in Ovarian Cancer

Gina Columbus @ginacolumbusonc
Published: Tuesday, Apr 11, 2017

Heather Dalton, MD

Heather Dalton, MD

In the frontline setting, chemotherapy regimens are still the go-to option for patients with ovarian cancer—and likely will be for years to come, explains Heather Dalton, MD.

State of the Science Summit on Ovarian Cancer, Dalton spoke about the first-line treatment options currently available for patients, pivotal data that have solidified standard approaches, and why chemotherapy will likely always remain critical in the ovarian cancer sphere.

OncLive: What are the options for patients in the first-line setting with ovarian cancer?

Dalton: Unfortunately, most of our patients with ovarian cancer are advanced when they are diagnosed, so we are always left with a conundrum on how to treat them. There has been a lot of research done about the best way to treat these patients. We have moved a long way from initially doing cytotoxic doxorubicin, to around 2003 where carboplatin and paclitaxel became the backbone for our ovarian cancer treatment. Since then, we’ve been looking at different ways to give it and ways to improve progression-free survival (PFS).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication